Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke prophylaxis; but more recently, a group of drugs known as novel oral anticoagulants have been developed. Apixaban belongs to this group of drugs, and is a factor Xa inhibitor that has emerged as a popular pharmacological agent worldwide. In this review, we will provide an overview of the pivotal trials in the development of apixaban, while also critically evaluating the new emerging real-world data, and discussing the effectiveness, safety, economic viability and future prospects of apixaban and how it impacts on patient outcomes in those with non-valvular atrial fibrillation.
CITATION STYLE
Ioannou, A., Tsappa, I., Metaxa, S., & Missouris, C. G. (2017). Non-valvular atrial fibrillation: impact of apixaban on patient outcomes. Patient Related Outcome Measures, Volume 8, 121–131. https://doi.org/10.2147/prom.s117549
Mendeley helps you to discover research relevant for your work.